Background: EZH2 is frequently mutated and/or overexpressed in numerous cancers. High EZH2 expression is correlated with poor outcomes in prostate cancer patients (Varambally, 2002). EZH2 inhibition combines synergistically with anti-androgen therapies in preclinical models of advanced prostate cancer, suggesting epigenetic reprogramming as a pathophysiologic mechanism to enhance the combination therapy (Ku, 2017; Xiao 2018; Constellation, unpublished). CPI-1205 is a potent, selective, and cofactor-competitive inhibitor of wild type and mutant EZH2 catalytic activity, which demonstrates anti-proliferative effects in prostate and other cancer cell models.
at the suggestion of my onco. enzalutamide is no longer effective and my condition is a bit premature for “hard” chemo so i’ve been switch to abiraterone with cp-1205 which is designed to help the immune system
Thanks will do. So far the fatigue is phenomenal. Nausea is very pronounced bit but i’ve managed to keep everything down. bad diarrhea yesterday, but no abdominal pain associated with it. a little unsteady on my feet. i hope my body gets accustomed to the symptoms and is able to tolerate them better or mitigate them to some degree.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.